4.7 Article

Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis

Journal

BLOOD
Volume 137, Issue 4, Pages 556-568

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood.2020006252

Keywords

-

Categories

Funding

  1. K07 award from the National Institutes of Health (NIH)/National Cancer Institute (NCI) [1K07CA211847]
  2. NIH/NCI Public Health Service [U24CA076518]
  3. NIH/National Heart, Lung and Blood Institute (NHLBI) [U24HL138660, OT3HL147741, R21HL140314, U01HL128568]
  4. NIH/Health Resources and Services Administration [HHSH250201700006C, SC1MC31881-01-00, HHSH250201700007C]
  5. Office of Naval Research [N00014-18-1-2850, N00014-18-1-2888, N00014-20-1-2705]
  6. NIH/NCI [P01CA111412, R01CA152108, R01CA215134, R01CA218285, R01CA231141]
  7. NIH/NHLBI [R01HL126589, R01HL129472, R01HL130388, R01HL131731]
  8. NIH/National Institute of Allergy and Infectious Diseases [R01AI128775, U01AI069197, U01AI126612]
  9. Biomedical Advanced Research and Development Authority
  10. Be theMatch Foundation
  11. Boston Children's Hospital
  12. Dana-Farber
  13. Japan Hematopoietic Cell Transplantation Data Center
  14. St Baldrick's Foundation
  15. National Marrow Donor Program
  16. Medical College of Wisconsin
  17. AbbVie
  18. Actinium Pharmaceuticals, Inc
  19. Adaptive Biotechnologies
  20. Adienne SA
  21. Allovir, Inc
  22. Amgen, Inc
  23. Anthem, Inc
  24. Astellas Pharma US
  25. AstraZeneca
  26. Atara Biotherapeutics, Inc
  27. bluebird bio, Inc
  28. Bristol Myers Squibb Co
  29. Celgene Corp
  30. Chimerix, Inc
  31. CSL Behring
  32. CytoSen Therapeutics, Inc
  33. Daiichi Sankyo Co, Ltd
  34. GamidaCell, Ltd
  35. Genzyme
  36. GlaxoSmithKline
  37. HistoGenetics, Inc
  38. Incyte Corp
  39. Janssen Biotech, Inc
  40. Janssen Pharmaceuticals, Inc
  41. Janssen/Johnson Johnson
  42. Jazz Pharmaceuticals, Inc
  43. Kiadis Pharma
  44. Kite Pharma
  45. Kyowa Kirin
  46. Legend Biotech
  47. Magenta Therapeutics
  48. Mallinckrodt, LLC
  49. Medac GmbH
  50. Merck Company, Inc
  51. Merck Sharp Dohme Corp
  52. Mesoblast
  53. Takeda Oncology Co
  54. Miltenyi Biotec, Inc
  55. Novartis Oncology
  56. Novartis Pharmaceuticals Corp
  57. Omeros Corp
  58. Oncoimmune, Inc
  59. Orca Biosystems, Inc
  60. Pfizer, Inc
  61. Phamacyclics, LLC
  62. Regeneron Pharmaceuticals, Inc
  63. REGiMMUNE Corp
  64. Sanofi Genzyme
  65. Seattle Genetics
  66. Sobi, Inc
  67. Takeda Oncology
  68. Takeda Pharma
  69. Terumo BCT
  70. Viracor Eurofins
  71. Xenikos BV
  72. Millennium

Ask authors/readers for more resources

This study aimed to investigate the impact of neighborhood poverty on outcomes of pediatric allogeneic HCT recipients, revealing that in malignant diseases, neighborhood poverty increased the risk of transplantation-related mortality but did not affect overall survival or other HCT outcomes; for nonmalignant diseases, neighborhood poverty had no association with HCT outcomes. Additionally, children with Medicaid insurance experienced worse overall survival and increased transplantation-related mortality in malignant diseases.
Social determinants of health, including poverty, contribute significantly to health outcomes in the United States; however, their impact on pediatric hematopoietic cell transplantation (HCT) outcomes is poorly understood. We aimed to identify the association between neighborhood poverty and HCT outcomes for pediatric allogeneic HCT recipients in the Center for International Blood and Marrow Transplant Research database. We assembled 2 pediatric cohorts undergoing first allogeneic HCT from 2006 to 2015 at age 518 years, including 2053 children with malignant disease and 1696 children with nonmalignant disease. Neighborhood poverty exposure was defined a priori per the US Census definition as living in a high-poverty ZIP code (>= 20% of persons below 100% federal poverty level) and used as the primary predictor in all analyses. Our primary outcome was overall survival (OS), defined as the time from HCT until death resulting from any cause. Secondary outcomes included relapse and transplantation-related mortality (TRM) in malignant disease, acute and chronic graft-versus-host disease, and infection in the first 100 days post-HCT. Among children undergoing transplantation for nonmalignant disease, neighborhood poverty was not associated with any HCT outcome. Among children undergoing transplantation for malignant disease, neighborhood poverty conferred an increased risk of TRM but was not associated with inferior OS or any other transplantation outcome. Among children with malignant disease, a key secondary finding was that children with Medicaid insurance experienced inferior OS and increased TRM compared with those with private insurance. These data suggest opportunities for future investigation of the effects of household-level poverty exposure on HCT outcomes in pediatric malignant disease to inform care delivery interventions.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Public, Environmental & Occupational Health

Risk of bacterial bloodstream infection does not vary by central-line type during neutropenic periods in pediatric acute myeloid leukemia

Caitlin W. Elgarten, William R. Otto, Luke Shenton, Madison T. Stein, Joseph Horowitz, Catherine Aftandilian, Staci D. Arnold, Kira O. Bona, Emi Caywood, Anderson B. Collier, M. Monica Gramatges, Meret Henry, Craig Lotterman, Kelly Maloney, Arunkumar J. Modi, Amir Mian, Rajen Mody, Elaine Morgan, Elizabeth A. Raetz, Anupam Verma, Naomi Winick, Jennifer J. Wilkes, Jennifer C. Yu, Richard Aplenc, Brian T. Fisher, Kelly D. Getz

Summary: There is no significant association between CVAD type and BSI occurrence during neutropenia in pediatric AML patients.

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2023)

Article Oncology

Accuracy of online medical information: the case of social media in sickle cell disease

Nichole Slick, Prasad Bodas, Sherif M. Badawy, Beth Wildman

Summary: This study assessed the accuracy of information about sickle cell disease (SCD) posted on social media and found that less than half of the information was accurate. This has serious implications for individuals with SCD and their caregivers who rely on social media for information.

PEDIATRIC HEMATOLOGY AND ONCOLOGY (2023)

Article Cell & Tissue Engineering

Editing human hematopoietic stem cells: advances and challenges

Senthil Velan Bhoopalan, Jonathan S. Yen, Rachel M. Levine, Akshay Sharma

Summary: Genome editing technologies, specifically CRISPR-Cas9, have made significant progress in precise genome alterations for the treatment of inherited hematopoietic disorders. Despite ongoing clinical trials and promising pre-clinical models, challenges still remain in ensuring safety, accessibility, and improving the manufacturing processes of these therapies. This review highlights recent advances and ongoing challenges in genome editing of hematopoietic stem and progenitor cells.

CYTOTHERAPY (2023)

Article Oncology

Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients

Michael Boyiadzis, Mei-Jie Zhang, Karen Chen, Hisham Abdel-Azim, Muhammad Bilal Abid, Mahmoud Aljurf, Ulrike Bacher, Talha Badar, Sherif M. Badawy, Minoo Battiwalla, Nelli Bejanyan, Vijaya Raj Bhatt, Valerie Brown, Paul Castillo, Jan Cerny, Edward A. Copelan, Charles Craddock, Bhagirathbhai Dholaria, Miguel Angel Diaz Perez, Christen L. Ebens, Robert Peter Gale, Siddhartha Ganguly, Lohith Gowda, Michael R. Grunwald, Shahrukh Hashmi, Gerhard C. Hildebrandt, Madiha Iqbal, Omer Jamy, Mohamed A. Kharfan-Dabaja, Nandita Khera, Hillard M. Lazarus, Richard Lin, Dipenkumar Modi, Sunita Nathan, Taiga Nishihori, Sagar S. Patel, Attaphol Pawarode, Akshay Sharma, Melhem Solh, John L. Wagner, Trent Wang, Kirsten M. Williams, Lena E. Winestone, Baldeep Wirk, Christopher S. Hourigan, Mark Litzow, Partow Kebriaei, Marcos de Lima, Kristin Page, Daniel J. Weisdorf

Summary: We investigated the impact of the number of induction/consolidation cycles on the outcomes of adult AML patients who received allo-HCT between 2008 and 2019. Our findings suggest that the number of induction cycles to complete remission (CR) has an impact on overall survival (OS) in patients who received myeloablative conditioning, with better OS observed in patients who achieved CR after 1 cycle compared to those who required 2 cycles or more. In contrast, the number of induction cycles did not affect OS in patients who received reduced-intensity conditioning. Consolidation therapy prior to allo-HCT was associated with improved OS in patients who achieved CR after 1 cycle. The presence of detectable minimal residual disease (MRD) at the time of allo-HCT did not impact outcomes in myeloablative allo-HCT, but was associated with an increased risk of relapse in reduced-intensity allo-HCT. Allo-HCT in patients with primary induction failure had significantly worse OS compared to allo-HCT in patients who achieved CR after 1-3 cycles.

LEUKEMIA (2023)

Letter Hematology

Diffuse myocardial fibrosis occurs in young patients with sickle cell anemia despite early disease-modifying therapy

Cara E. Morin, Akshay Sharma, Subodh Selukar, Gary Beasley, Anthony Merlocco, Chris Goode, Parul Rai, Jeffrey A. Towbin, Jane S. Hankins, Jason N. Johnson

BLOOD (2023)

Article Oncology

Barriers to medication adherence in sickle cell disease: A comprehensive theory-based evaluation using the COM-B model

Kathryn King, Stephanie Cai, Leonardo Barrera, Paavani Reddy, Mallorie B. Heneghan, Sherif M. Badawy

Summary: This study aimed to investigate barriers to hydroxyurea adherence and evaluate their impact on adherence. The results showed that patients with good adherence had fewer barriers. Understanding barriers to adherence is crucial for improving adherence.

PEDIATRIC BLOOD & CANCER (2023)

Article Hematology

An evaluation of deferiprone as twice-a-day tablets or in combination therapy for the treatment of transfusional iron overload in thalassemia syndromes

Richa Shah, Aashaka Shah, Sherif M. Badawy

Summary: Regular blood transfusions in thalassemia patients can lead to iron overload and related complications. Deferiprone, one of the FDA-approved iron chelators, is effective at reducing iron levels and has gained approval for twice-daily administration.

EXPERT REVIEW OF HEMATOLOGY (2023)

Review Hematology

Provider prescription of hydroxyurea in youth and adults with sickle cell disease: A review of prescription barriers and facilitators

Alex Pizzo, Jerlym S. Porter, Yvonne Carroll, Adam Burcheri, Matthew P. Smeltzer, Molly Beestrum, Chinonyelum Nwosu, Sherif M. Badawy, Jane S. Hankins, Lisa M. Klesges, Nicole M. Alberts

Summary: Sickle cell disease is associated with frequent painful events and organ damage. Hydroxyurea is the recommended treatment, but prescription rates are low. Provider barriers include doubts around patient adherence, concerns about side effects, lack of knowledge, cost, and patient concerns. Provider attitudes and knowledge play a role in prescription rates.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Review Radiology, Nuclear Medicine & Medical Imaging

Cancer Therapy-related Hepatic Injury in Children: Imaging Review from the Pediatric LI-RADS Working Group

Cara E. Morin, Amy B. Kolbe, Adina Alazraki, Govind B. Chavhan, Annie Gill, Juan Infante, Geetika Khanna, HaiThuy N. Nguyen, Allison F. O'Neill, Mitchell A. Rees, Akshay Sharma, James E. Squires, Judy H. Squires, Ali B. Syed, Elizabeth R. Tang, Alexander J. Towbin, Gary R. Schooler

Summary: Treatment-induced liver injury is common in children undergoing cancer therapy and can occur during and after treatment. It can result in various acute and long-term effects, including liver failure. Quantitative imaging techniques can be useful for diagnosing and monitoring liver injury. Treatment-related liver lesions and infections can be mistaken for cancer recurrence or liver metastases, but imaging features can help differentiate them. Radiologic evaluation is essential for diagnosing and monitoring hepatic complications of cancer therapy in pediatric patients.

RADIOGRAPHICS (2023)

Article Oncology

Interplay Effect of Splenic Motion for Total Lymphoid Irradiation in Pediatric Proton Therapy

Ozgur Ates, Jinsoo Uh, Fakhriddin Pirlepesov, Chia-Ho Hua, Brandon Triplett, Amr Qudeimat, Akshay Sharma, Thomas E. Merchant, John T. Lucas Jr

Summary: This study addresses the challenge of respiratory motion in pediatric patients undergoing proton therapy for total lymphoid irradiation (TLI). The research concludes that 4D plan evaluation and robust optimization techniques can help address respiratory motion challenges in proton TLI treatments. Patient-specific respiratory motion evaluations are crucial to ensure adequate dosimetric coverage in proton therapy for pediatric patients.

CANCERS (2023)

Review Oncology

Hematopoietic cell transplantation and gene therapy for Diamond-Blackfan anemia: state of the art and science

Senthil Velan Bhoopalan, Shruthi Suryaprakash, Akshay Sharma, Marcin W. Wlodarski

Summary: Diamond-Blackfan anemia is a common genetic cause of bone marrow failure in children, characterized by anemia and bone marrow hypoplasia. It is associated with congenital anomalies, immunodeficiency, and increased risk of malignancies. Corticosteroids provide temporary relief for anemia, but most patients require lifelong blood transfusions. Allogeneic hematopoietic cell transplantation is a potential curative option, but with significant risks. Autologous genetic therapies are being developed to address the lack of suitable donors.

FRONTIERS IN ONCOLOGY (2023)

Article Hematology

Impact of Public Reporting of Center-Specific Survival Analysis Scores on Patient Volumes at Hematopoietic Cell Transplant Centers

Akshay Sharma, Brent Logan, Noel Estrada-Merly, Leslie E. Lehmann, Hemalatha G. Rangarajan, Jaime M. Preussler, Jesse D. Troy, Luke P. Akard, Neel S. Bhatt, Tony H. Truong, William A. Wood, Christopher Strouse, Mark Juckett, Nandita Khera, Douglas Rizzo, Wael Saber

Summary: This article focuses on the impact of public reporting of transplantation center performance on patient volumes. The study found that if a center has a lower than expected survival rate, the number of patients in the following year will decrease. In contrast, neighboring centers to those with lower survival rates experienced an increase in patient volumes.

TRANSPLANTATION AND CELLULAR THERAPY (2023)

Article Hematology

Demographics, Motivations, and Experiences of Participants in Transplantation or Cellular Therapy Fellowships

Rahul Banerjee, Amar H. Kelkar, Urshila Durani, Theodora Anagnostou, Miki Nishitani, Kanwaldeep Mallhi, Navneet S. Majhail, Aaron C. Logan

Summary: Recent guidelines from the American Society for Transplantation and Cellular Therapy have aimed to establish expectations for participants in blood and marrow transplantation (BMT) and cellular therapy (CT) fellowships. A survey was conducted to examine the demographics, motivations, and experiences of recent participants in BMT/CT fellowships. The results showed that the fellowship training had a positive impact on participants' comfort with BMT/CT management and the majority would highly recommend this training to others.

TRANSPLANTATION AND CELLULAR THERAPY (2023)

Article Hematology

A Pilot Trial of Patient-Reported Outcomes for Acute Graft-Versus-Host-Disease

Sagar S. Patel, Sanghee Hong, Lisa Rybicki, Stephanie Farlow, Jane Dabney, Matt Kalaycio, Ronald Sobecks, Navneet S. Majhail, Betty K. Hamilton

Summary: Acute graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic cell transplantation (HCT), causing significant physical and psychosocial symptoms. This pilot study aimed to assess the feasibility of using patient-reported outcome (PRO) measures to evaluate symptom burden and quality of life (QOL) in acute GVHD. The study utilized surveys from various PRO measures and found that patients with acute GVHD had lower QOL scores compared to those without or with mild GVHD. The PRO-CTCAE captured several common symptoms of acute GVHD. Challenges in implementing PRO measures in acute GVHD were identified. Further research is needed to make PROs feasible in this patient population.

TRANSPLANTATION AND CELLULAR THERAPY (2023)

Article Hematology

Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma

Rajshekhar Chakraborty, Jean Yi, Lisa Rybicki, Jaime Preussler, Abhinav Deol, Alison Loren, Bipin Savani, Heather S. L. Jim, Jan Cerny, Jana Reynolds, Jennifer Whitten, John R. Wingard, Joseph P. McGuirk, Joseph Uberti, Nandita Khera, Patrick Stiff, Samantha M. Jaglowski, Shahrukh Hashmi, Shernan G. Holtan, Steven Devine, Theresa Hahn, Victoria L. Whalen, Wael Saber, William Wood, K. Scott Baker, Karen Syrjala, Navneet S. Majhail

Summary: Survivors of autologous hematopoietic cell transplantation (AHCT) for multiple myeloma in stable remission do not have clinically meaningful worsening in physical functioning compared to the general population. However, they may experience distress related to health burden, uncertainty, and finances. Adherence to preventive care guidelines is high, but adherence to exercise and diet guidelines is relatively low.

TRANSPLANTATION AND CELLULAR THERAPY (2023)

No Data Available